Clinical Trial Update: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating everolimus (RAD001) in combination with octreotide depot in metastatic or unresectable low-grade neuroendocrine tumors completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Afinitor (everolimus)
• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Neuroendocrine Carcinoma, Islet Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2010-12-07